Multiple Faces Of Indirubin And Its Analogues In Fighting Cancer

Long G. Wang,Simon K. Mencher

2006-01-01

Abstract:Recent progress made in understanding the mechanisms leading to the dysfunction of signaling pathways and cellular regulation, both intimately involved in the pathological processes of diseases, has lead to revolutionary changes in drug discovery. This new strategy aims at finding a drug that selectively targets a signaling pathway involved in disease pathogenesis through combinatorial chemistry-based high-throughout screening or by using computer-aided rational drug design. However, attempts to develop more effective treatments for diseases in this manner, such as for cancer and neurodegenerative diseases, using drugs selective for single molecular targets have been problematic. Fatal heart attacks linked to VIOXX (rofecoxib), a selective Cox 2 inhibitor, has lead to the withdrawal of VIOXX from the market. This situation has highlighted the problems associated with molecular targeting strategies based on selectivity In contrast to targetting single molecules, the use of indirubin, a component of traditional Chinese medicine (TCM), is promiscuous (non-selective) in that it targets several signaling pathways simultaneously. The targets include those involved with cell cycle regulation, growth factor receptor signaling (Stat3) and AhR signaling. Although the specific mechanisms involved have not yet been fully elucidated, in this chapter, we describe the current understand of mechanism of activity of indirubin, its analogues indigo and isoindigo, as well as related derivatives in fighting cancer.